Immunomodulation for the prevention of SPIDDM and LADA

Annals of the New York Academy of Sciences

Volumn 1079, Issue , 2006, Pages 90-98

  Pozzilli, Paolo ^a,b   Guglielmi, C ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Diabetes; GAD antibodies; Immunotherapy; LADA; SPIDDM

Indexed keywords

AUTOANTIBODY; CALCITRIOL; DIAPEP 277; GLITAZONE DERIVATIVE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE ANTIBODY; HEAT SHOCK PROTEIN 60; IMMUNOMODULATING AGENT; INSULIN; INSULIN ANTIBODY; INSULINOMA ASSOCIATED ANTIBODY; ORAL ANTIDIABETIC AGENT; PANCREAS ISLET CELL ANTIBODY; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ADOLESCENCE; AGE DISTRIBUTION; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; CELL DESTRUCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LATENT AUTOIMMUNE DIABETES MELLITUS; MONOTHERAPY; NONHUMAN; PANCREAS ISLET CELL; PREVENTIVE MEDICINE; PROGRESSIVE INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

EID: 33845703983     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1375.012     Document Type: Conference Paper

References (29)

1. FOURLANOS, S., F. DOTTA, C.J. GREENBAUM, et al. 2005. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48: 2206-2212.
2. TUOMI, T., L.C. GROOP, P.Z. ZIMMET, et al. 1993. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non insulin-dependent onset of disease. Diabetes 42: 359-362.
3. ZIMMET, P., T. TUOMI, I.R. MACKAY, et al. 1994. Latent autoimmune diabetes mellitus in adult (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet. Med. 11: 299-303.
4. LESLIE, R.D. & P. POZZILLI. 1994. Type I diabetes masquerading as type II diabetes. Possible implications for prevention and treatment. Diabetes Care 17: 1214-1219.
5. POZZILLI, P. & U. DI MARIO. 2001. Autoimmune diabetes not requiring insulin at diagnosis (Latent Autoimmune Diabetes of the Adult): definition, characterization and potential prevention. Diabetes Care 24: 1460-1467.
6. AMERICAN DIABETES ASSOCIATION. DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS. 2004. Diabetes Care. 27: S5-S10.
7. BONIFACIO, E., S. GENOVESE, S. BRAGHI, et al. 1995. Islet autoantibody markers in insulin dependent diabetes: identification of screening strategies yielding high sensitivity. Diabetologia 38: 816-822.
8. BONIFACIO, E., V. LAMPASONA, S. GENOVESE, et al. 1995. Identification of protein tyrosine phosphatase-like IA-2 (Islet Cell Antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J. Immunol. 155: 5419-5426.
9. BONIFACIO, E., V. LAMPASPONA & P.J. BINGLEY. 1998. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes mellitus-associated tyrosine phosphate autoantigens. J. Immunol. 161: 2648-2654.
10. VERGE, C.F., D. STENGER, E. BONIFACIO, et al. 1998. Combined use of autoantibodies (IA-2autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes mellitus: combinatorial islet autoantibody workshop. Diabetes 47: 1857-1866.
11. TURNER, R., I. STRATTON, V. HORTON, et al. for UK Prospective Diabetes Study (UKPDS) Group. 1997. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350: 1288-1293.
12. KOBAYASHI, T., K. TAMEMOTO, K. NAKANISHI, et al. 1993. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16: 780-788.
13. POZZILLI, P. & U. DI MARIO. 2001. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 24: 1460-1467.
14. POZZILLI, P., N. VISALLI, R. BUZZETTI, et al. 1998. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. IMDIAB Study Group. Immun. Diabetes Metab. 47: 1205-1210.
15. RAZ, I., D. ELIAS, A. AVRON, et al. 2001. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358: 1749-1753.
16. KAUFMAN, D.L., M. CLARE-SALZLER, J. TIAN, et al. 1993. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69-72.
17. TIAN, J., M.A. ATKINSON, M. CLARE-SALZLER, et al. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183: 1-7.
18. TIAN, J., M. CLARE-SALZLER, A. HERSCHENFELD, et al. 1996. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat. Med. 2: 1348-1353.
19. TISCH, R., R.S. LIBLAU, X.D. YANG, et al. 1998. Induction of GAD65-specific regulatory T-cells inhibits on going autoimmune diabetes in non obese diabetic mice. Diabetes 47: 894-899.
20. AGARDH, C.D., C.M. CILIO, A. LETHAGEN, et al. 2005. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Comp. 19: 238-246.
21. NAKANISHI, K., T. KOBAYASHI, H. INOKO, et al. 1995. Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44: 1334-1339.
22. MARUYAMA, T., A. SHIMADA, A. KANATSUKA, et al. 2003. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann. N. Y. Acad. Sci. 1005: 362-369.
23. GIULIETTI, A., C. GYSEMANS, K. STOFFELS, et al. 2004. Vitamin D deficiency in early life accelerates type 1 diabetes in non-obese diabetic mice. Diabetologia 47: 451-462.
24. DELUCA, H.F. & M.T. CANTORNA. 2001. Vitamin D: its role and uses in immunology. FASEB J. 14: 2579-2585.
25. HYPPONEN, E., E. LÄÄRÄ, A. REUNANEN, et al. 2001. Intake of vitamin D and risk of type 1 diabetes: a birth cohort study. Lancet 358: 1500-1503.
26. PITOCCO, D., A. CRINÒ, E. DI STASIO, et al. 2005. on behalf of the IMDIAB Group. A randomized pilot trial of calcitriol versus nicotinamide in patients with recent onset type 1 diabetes (IMDIAB XI). Diabetic Med. In press.
27. ZHOU, Z., N. LIAO, X. LI & M. LEI. 2005. Vitamin D supplementation in adults with latent autoimmune diabetes (LADA) [abstract]. Diabetologia 48: A87.
28. BEALES, P.E. & P. POZZILLI. 2002. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab. Res. Rev. 18: 114-117.
29. ZHOU, Z., X. LI, G. HUANG, et al. 2005. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 21: 203-208.